Elanco Animal Health Inc(ELAN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 5:05 PM ET (Korea 10/29 06:05)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.4 | Insider Own | 1.02% | Shs Outstand | 499.6M | Perf Week | 0.44% |
| Market Cap | 11.32B | Forward P/E | 17.9 | EPS next Y | 11.74% | Insider Trans | 1.37% | Shs Float | 494.5M | Perf Month | 0.18% |
| Enterprise Value | 14.70B | PEG | 1.2 | EPS next Q | 0.2 | Inst Own | 115.09% | Short Float | 6.29% | Perf Quarter | -14.4% |
| Income | -0.20B | P/S | 2.25 | EPS this Y | 20.46% | Inst Trans | 4.23% | Short Ratio | 4.98 | Perf Half Y | 3.9% |
| Sales | 5.02B | P/B | 1.72 | EPS next 5Y | 14.87% | ROA | -1.46% | Short Interest | 31.11M | Perf YTD | 0.09% |
| Book/sh | 13.19 | P/C | 21.35 | EPS past 3/5Y | -43.04% 18.11% | ROE | -2.98% | 52W High | -19.05% ($27.98) | Perf Year | 2.4% |
| Cash/sh | 1.06 | P/FCF | 29.86 | Sales past 3/5Y | 2.25% 7.57% | ROIC | -1.91% | 52W Low | 16.75% ($19.40) | Perf 3Y | 155.93% |
| Dividend Est. | - | EV/EBITDA | 14.33 | EPS Y/Y TTM | -145.71% | Gross Margin | 44.28% | Volatility(W/M) | 2.87% 3.07% | Perf 5Y | -31.16% |
| Dividend TTM | - | EV/Sales | 2.93 | Sales Y/Y TTM | 11.95% | Oper. Margin | 6.63% | ATR (14) | 0.7 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.1 | EPS Q/Q | 380.63% | Profit Margin | -3.96% | RSI (14) | 47.49 | Recom | 1.35 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.05 | Sales Q/Q | 10.23% | SMA20 | -0.12% ($22.68) | Beta | 1.74 | Target Price | $30.5 |
| Payout | - | Debt/Eq | 0.59 | Earnings | 2026/11/6 | SMA50 | -2.2% ($23.16) | Rel Volume | 0.7 | Prev Close | $22.65 |
| Employees | 9900 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | 26.3% 4.23% | SMA200 | -4.85% ($23.8) | Avg Volume(3M) | 6.25M | Price | $22.65 |
| IPO | 2018/9/20 | Option/Short | Yes/Yes | Trades | 23976 | Volume | 4,393,979 | Change | - |
A US-based animal health company that develops and manufactures pharmaceuticals and vaccines for both companion animals and livestock, supplying veterinarians and livestock producers worldwide as a global animal healthcare leader. The company was spun off from Eli Lilly and operates as an independent publicly traded entity.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
Next earnings report: November 6
9 days to go.
ELAN keeps an operating profit but posts a net loss
Of every $100 in sales, $6.63 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $225. Peers typically go for $225. Compared with its own 1-year average, it is 1471% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -31.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 115.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
ADPV Adaptiv Select ETF 0.04% 
IHE iShares U.S. Pharmaceuticals ETF 0.03% 
BSMC Brandes U.S. Small-Mid Cap Value ETF 0.03% 
JHAC John Hancock Fundamental All Cap Core ETF 0.02% 
TMED T. Rowe Price Health Care ETF 0.02% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
EIRL iShares MSCI Ireland ETF 76M 
GLCR GlacierShares Nasdaq Iceland ETF 1M 
TELG Leverage Shares 2X Long TEL Daily ETF - It ranks #9 of 83 in the industry
Based on market cap of $11B.
FAQ
What kind of company is ELAN?
ELAN belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ELAN?
The market cap of ELAN is approximately $11.3B, ranking 852 within its sector.
What is the 52-week high and low for ELAN?
ELAN has recorded a 52-week high of $27.98 and a low of $19.40.
